Department of Anesthesiology, Leiden University Medical Center , Leiden , The Netherlands.
Livingston , UK.
Expert Opin Drug Saf. 2019 Oct;18(10):883-891. doi: 10.1080/14740338.2019.1649393. Epub 2019 Aug 7.
: Sugammadex is a modified cyclodextrin that is able to reverse neuromuscular block induced by aminosteroidal neuromuscular blocking drugs. Compared to reversal with neostigmine, it reverses neuromuscular block quicker and more predictable and without cholinergic side effects. However, there have been concerns about sugammadex ability to bind other drugs and its effects on QT interval and clotting times. In addition, sugammadex might induce hypersensitivity reactions more frequently than initially anticipated. This review summarizes current evidence with regard to these and other safety aspects of sugammadex. : This review provides an overview of the efficacy of sugammadex in various patient populations, evaluates potential interactions with other drugs and discusses adverse effects and reactions that have been reported in the literature. : Sugammadex quickly reverses aminosteroid neuromuscular block with less side effects compared to neostigmine. As such, it has the potential to significantly reduce the incidence of residual neuromuscular block and to improve postoperative pulmonary outcome. Current safety concerns mainly focus on hypersensitivity reactions and cardiac arrhythmias. Although the absolute risk for these events is low, ongoing vigilance and research in this area are needed.
: 氨甲酰基衍生物是一种改良的环糊精，能够逆转由氨基甾体类神经肌肉阻断剂引起的神经肌肉阻滞。与新斯的明逆转相比，它能更快、更可预测地逆转神经肌肉阻滞，且没有胆碱能副作用。然而，人们一直担心氨甲酰基衍生物结合其他药物的能力及其对 QT 间期和凝血时间的影响。此外，与最初预期相比，氨甲酰基衍生物可能更频繁地引发过敏反应。这篇综述总结了关于氨甲酰基衍生物的这些和其他安全方面的现有证据。 : 这篇综述提供了氨甲酰基衍生物在各种患者群体中的疗效概述，评估了与其他药物的潜在相互作用，并讨论了文献中报道的不良反应和反应。 : 与新斯的明相比，氨甲酰基衍生物能更快地逆转氨基甾体类神经肌肉阻滞，且副作用更少。因此，它有可能显著降低残余神经肌肉阻滞的发生率，并改善术后肺部结局。目前的安全关注点主要集中在过敏反应和心律失常上。尽管这些事件的绝对风险较低，但仍需要持续关注和研究这一领域。
